MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.35% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-09-30 was 1.89%, a 37.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.65%, a 2.21% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-09-30 was 3.00%, a 9.09% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-06-30 was 2.89%, a 38.28% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.35%, a 7.25% decline from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.69%, a 0.00% change from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.69%, a 8.56% increase from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.32%, a 237.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 4.35% 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | 4.69% 10-K · filed 2025-04-15 | ||||
| 2023-12-31 | 4.69% 10-K · filed 2024-03-27 | ||||
| 2022-12-31 | 4.32% 10-K · filed 2024-03-27 | ||||
| 2021-12-31 | 1.28% 10-K · filed 2023-03-15 | ||||
| 2020-12-31 | 1.74% 10-K/A · filed 2022-03-11 | ||||
| 2019-12-31 | 2.65% 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | 1.89% 10-Q · filed 2019-11-13 | 2.65% 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | 2.65% 10-Q · filed 2019-08-13 | ||||
| 2019-03-31 | 2.65% 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | 3.08% 10-K · filed 2020-03-09 | ||||
| 2018-09-30 | 3.00% 10-Q · filed 2019-11-13 | 3.00% 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | 2.89% 10-Q · filed 2019-08-13 | 2.89% 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | 2.71% 10-Q · filed 2019-05-13 | ||||
| 2017-12-31 | 2.37% 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | 2.75% 10-Q · filed 2018-11-09 | 2.08% 10-Q · filed 2017-11-14 | 2.22% 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | 2.09% 10-Q · filed 2018-08-09 | 2.22% 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | 2.22% 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | 2.09% 10-K · filed 2018-03-16 | ||||
| 2016-09-30 | 1.28% 10-Q · filed 2017-11-14 | 1.42% 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | 1.38% 10-Q · filed 2017-08-08 | 1.38% 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | 1.38% 10-Q · filed 2016-05-13 | ||||
| 2015-12-31 | 1.74% 10-K · filed 2018-03-16 | ||||
| 2015-09-30 | 1.72% 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | 1.85% 10-Q · filed 2016-08-15 | ||||
| 2015-03-31 | 1.93% 10-Q · filed 2016-05-13 | ||||
| 2014-12-31 | 1.93% 10-K · filed 2016-03-30 | ||||
| 2013-12-31 | 2.15% 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |